Drug & intervention

hydroxyurea

RxCUI 5552

Clinical trials22
Recruiting2
Related conditions16
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Hydroxycarbamide

Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. In sickle-cells disease it increases fetal hemoglobin and decreases the number of attacks. It is taken by mouth. Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancer. Use during pregnancy is typically harmful to the fetus. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA. Hydroxycarbamide was approved for medical use in the United States in 1967. It is on the World Health Organization's List of Essential Medicines. Hydroxycarbamide is available as a generic medication.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

22 shown
Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureNCT03500731 · 2018-04-19
RECRUITING
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · 2014-02-04
RECRUITING
Hydroxyurea in Pulmonary Arterial HypertensionNCT01950585 · 2013-09-06
WITHDRAWN
Hydroxyurea in Primary Progressive Multiple SclerosisNCT01103583 · 2011-07-01
TERMINATED
Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary HypertensionNCT00350844 · 2006-07-01
TERMINATED
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral SuppressionNCT00344981 · 2003-06-01
COMPLETED
Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentNCT00005018 · 1999-07-01
COMPLETED
Combination Drug Treatment of Pediatric HIV InfectionNCT00001818 · 1999-06-01
COMPLETED
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected AdultsNCT00002427 · 1999-05-01
COMPLETED
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV InfectionNCT00002176 · 1997-05-01
COMPLETED
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV InfectionNCT00002177 · 1997-05-01
COMPLETED
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung CancerNCT00002887 · 1995-07-01
UNKNOWN
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionNCT00006339
WITHDRAWN
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected PatientsNCT00001074
COMPLETED
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyNCT00008866
WITHDRAWN
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their BloodNCT00000916
COMPLETED
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as PossibleNCT00000939
COMPLETED
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV InfectionNCT00000919
COMPLETED
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsNCT00002420
TERMINATED
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsNCT00002418
TERMINATED
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected PatientsNCT00002230
COMPLETED
A Study of MKC-442 in Combination With Other Anti-HIV DrugsNCT00002412
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.